Table 3 List of 77 statistically significant pathways targeted by differentially modulated miRNAs identified using Diana Tool software (miRPath v.3)

1

Mucin type O-Glycan biosynthesis

5.16E-15

27

41

2

Proteoglycans in cancer

1.17E-11

165

63

3

Pathways in cancer

1.43E-07

312

67

4

Arrhythmogenic right ventricular cardiomyopathy (ARVC)

5.37–07

62

56

5

Hippo signalling pathway

5.37E-07

124

64

6

Renal cell carcinoma

8.87E-07

60

56

7

ECM-receptor interaction

6.54E-06

66

55

8

Axon guidance

6.54E-06

104

60

9

ErbB signalling pathway

1.03E-05

75

55

10

TGF-beta signalling pathway

1.67E-05

68

55

11

Thyroid hormone signalling pathway

1.67E-05

98

61

12

Signalling pathways regulating pluripotency of stem cells

3.42E-05

114

61

13

Adherens junction

5.07E-05

65

60

14

Focal adhesion

5.07E-05

165

64

15

Ras signalling pathway

5.07E-05

177

68

16

Rap1 signalling pathway

5.27E-05

167

62

17

Lysine degradation

1.13E-04

39

57

18

Bacterial invasion of epithelial cells

3.08E-04

65

60

19

Glutamatergic synapse

3.79E-04

90

60

20

Endocytosis

3.79E-04

163

62

21

Glioma

4.34E-04

53

53

22

Adrenergic signalling in cardiomyocytes

6.85E-04

113

61

23

Pancreatic cancer

7.03E-04

56

54

24

Morphine addiction

7.88E-04

74

59

25

Phosphatidylinositol signalling system

8.54E-04

63

55

26

Adipocytokine signalling pathway

1.07E-03

58

57

27

Gap junction

1.78E-03

70

59

28

Oxytocin signalling pathway

2.12E-03

122

59

29

MAPK signalling pathway

2.13E-03

192

66

30

cAMP signalling pathway

2.20E-03

153

65

31

Platelet activation

2.36E-03

103

62

32

Circadian rhythm

3.00E-03

29

42

33

AMPK signalling pathway

3.00E-03

96

62

34

Neurotrophin signalling pathway

3.00E-03

96

65

35

FoxO signalling pathway

3.16E-03

105

59

36

Small cell lung cancer

3.21E-03

70

52

37

Regulation of actin cytoskeleton

4.44E-03

162

61

38

PI3K-Akt signalling pathway

4.69E-03

252

65

39

mTOR signalling pathway

4.73E-03

50

51

40

Estrogen signalling pathway

4.73E-03

76

58

41

Chronic myeloid leukemia

4.83E-03

61

54

42

Prostate cancer

4.89E-03

71

57

43

Ubiquitin mediated proteolysis

5.43E-03

105

60

44

Dorso-ventral axis formation

5.73E-03

25

37

45

Long-term depression

6.81E-03

46

51

46

Prolactin signalling pathway

6.81E-03

56

55

47

Protein processing in endoplasmic reticulum

8.06E-03

122

67

48

Acute myeloid leukemia

8.36E-03

47

52

49

Prion diseases

1.05E-02

22

38

50

Retrograde endocannabinoid signalling

1.05E-02

77

56

51

Colorectal cancer

1.05E-02

50

56

52

Choline metabolism in cancer

1.05E-02

79

60

53

Dilated cardiomyopathy

1.21E-02

70

52

54

GABAergic synapse

1.25E-02

64

54

55

Other types of O-glycan biosynthesis

1.43E-02

24

36

56

T cell receptor signalling pathway

1.43E-02

81

53

57

Gastric acid secretion

1.58E-02

60

54

58

Endometrial cancer

1.58E-02

43

56

59

Circadian entrainment

1.63E-02

77

62

60

Amoebiasis

1.64E-02

78

55

61

p53 signalling pathway

1.64E-02

55

51

62

Chagas disease (American trypanosomiasis)

1.67E-02

77

52

63

Non-small cell lung cancer

1.73E-02

44

51

64

Cholinergic synapse

1.92E-02

85

57

65

Glycosaminoglycan biosynthesis - heparan sulfate / heparin

2.30E-02

19

40

66

Hepatitis B

3.16E-02

102

61

67

cGMP-PKG signalling pathway

3.16E-02

122

63

68

Calcium signalling pathway

3.31E-02

131

61

69

Melanoma

3.46E-02

56

52

70

HIF-1 signalling pathway

3.56E-02

79

55

71

Hypertrophic cardiomyopathy (HCM)

3.63E-02

63

51

72

Shigellosis

3.68E-02

50

52

73

Cocaine addiction

3.82E-02

37

46

74

Wnt signalling pathway

4.33E-02

105

62

75

Caffeine metabolism

4.71E-02

5

10

76

Dopaminergic synapse

4.71E-02

97

65

77

Thyroid hormone synthesis

4.86E-02

52

50